

ICD-10 Procedure Coding System (ICD-10-PCS) 2025 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

005

No change	<i>Section</i>	0	Medical and Surgical	
	<i>Body System</i>	0	Central Nervous System and Cranial Nerves	
	<i>Operation</i>	5	Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent	
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device</i>
FY2025	0 Brain		0 Open 4 Percutaneous Endoscopic	Z No Device
FY2025	0 Brain		3 Percutaneous	Z No Device
No change	1 Cerebral Meninges 2 Dura Mater 6 Cerebral Ventricle 7 Cerebral Hemisphere 8 Basal Ganglia 9 Thalamus A Hypothalamus B Pons C Cerebellum D Medulla Oblongata F Olfactory Nerve G Optic Nerve H Oculomotor Nerve J Trochlear Nerve K Trigeminal Nerve L Abducens Nerve M Facial Nerve N Acoustic Nerve P Glossopharyngeal Nerve Q Vagus Nerve R Accessory Nerve S Hypoglossal Nerve T Spinal Meninges		0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device
FY2025	W Cervical Spinal Cord X Thoracic Spinal Cord Y Lumbar Spinal Cord		0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device
				3 Laser Interstitial Thermal Therapy Z No Qualifier

00K

No change	<i>Section</i>	0	Medical and Surgical	
	<i>Body System</i>	0	Central Nervous System and Cranial Nerves	
	<i>Operation</i>	K	Map: Locating the route of passage of electrical impulses and/or locating functional areas in a body part	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2025	0 Brain	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
FY2025	0 Brain	X External	Z No Device	1 Connectomic Analysis
FY2025	7 Cerebral Hemisphere 8 Basal Ganglia 9 Thalamus A Hypothalamus B Pons C Cerebellum D Medulla Oblongata	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier

041

	<i>Section</i>	0	Medical and Surgical
No change	<i>Body System</i>	4	Lower Arteries
	<i>Operation</i>	1	Bypass: Altering the route of passage of the contents of a tubular body part
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>
No change	0 Abdominal Aorta C Common Iliac Artery, Right D Common Iliac Artery, Left	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device
			0 Abdominal Aorta 1 Celiac Artery 2 Mesenteric Artery 3 Renal Artery, Right 4 Renal Artery, Left 5 Renal Artery, Bilateral 6 Common Iliac Artery, Right 7 Common Iliac Artery, Left 8 Common Iliac Arteries, Bilateral 9 Internal Iliac Artery, Right B Internal Iliac Artery, Left C Internal Iliac Arteries, Bilateral D External Iliac Artery, Right F External Iliac Artery, Left G External Iliac Arteries, Bilateral H Femoral Artery, Right J Femoral Artery, Left K Femoral Arteries, Bilateral Q Lower Extremity Artery R Lower Artery
FY2025	3 Hepatic Artery 4 Splenic Artery	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device
No change	E Internal Iliac Artery, Right F Internal Iliac Artery, Left H External Iliac Artery, Right J External Iliac Artery, Left	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device
			9 Internal Iliac Artery, Right B Internal Iliac Artery, Left C Internal Iliac Arteries, Bilateral D External Iliac Artery, Right F External Iliac Artery, Left G External Iliac Arteries, Bilateral H Femoral Artery, Right J Femoral Artery, Left K Femoral Arteries, Bilateral P Foot Artery Q Lower Extremity Artery
No change	K Femoral Artery, Right L Femoral Artery, Left	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device
			H Femoral Artery, Right J Femoral Artery, Left K Femoral Arteries, Bilateral L Popliteal Artery M Peroneal Artery N Posterior Tibial Artery P Foot Artery Q Lower Extremity Artery S Lower Extremity Vein
No change	K Femoral Artery, Right L Femoral Artery, Left	3 Percutaneous	J Synthetic Substitute
			Q Lower Extremity Artery S Lower Extremity Vein

No change	M Popliteal Artery, Right N Popliteal Artery, Left	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device	L Popliteal Artery M Peroneal Artery P Foot Artery Q Lower Extremity Artery S Lower Extremity Vein
No change	M Popliteal Artery, Right N Popliteal Artery, Left	3 Percutaneous	J Synthetic Substitute	Q Lower Extremity Artery S Lower Extremity Vein
No change	P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	J Synthetic Substitute	Q Lower Extremity Artery S Lower Extremity Vein
No change	T Peroneal Artery, Right U Peroneal Artery, Left V Foot Artery, Right W Foot Artery, Left	0 Open 4 Percutaneous Endoscopic	9 Autologous Venous Tissue A Autologous Arterial Tissue J Synthetic Substitute K Nonautologous Tissue Substitute Z No Device	P Foot Artery Q Lower Extremity Artery S Lower Extremity Vein
No change	T Peroneal Artery, Right U Peroneal Artery, Left V Foot Artery, Right W Foot Artery, Left	3 Percutaneous	J Synthetic Substitute	Q Lower Extremity Artery S Lower Extremity Vein

047

No change	<p><i>Section</i> 0 Medical and Surgical</p> <p><i>Body System</i> 4 Lower Arteries</p> <p><i>Operation</i> 7 Dilation: Expanding an orifice or the lumen of a tubular body part</p>			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2025	<p>0 Abdominal Aorta</p> <p>1 Celiac Artery</p> <p>2 Gastric Artery</p> <p>3 Hepatic Artery</p> <p>4 Splenic Artery</p> <p>5 Superior Mesenteric Artery</p> <p>6 Colic Artery, Right</p> <p>7 Colic Artery, Left</p> <p>8 Colic Artery, Middle</p> <p>9 Renal Artery, Right</p> <p>A Renal Artery, Left</p> <p>B Inferior Mesenteric Artery</p> <p>C Common Iliac Artery, Right</p> <p>D Common Iliac Artery, Left</p> <p>E Internal Iliac Artery, Right</p> <p>F Internal Iliac Artery, Left</p> <p>H External Iliac Artery, Right</p> <p>J External Iliac Artery, Left</p> <p>V Foot Artery, Right</p> <p>W Foot Artery, Left</p> <p>Y Lower Artery</p>	<p>0 Open</p> <p>3 Percutaneous</p> <p>4 Percutaneous Endoscopic</p>	<p>4 Intraluminal Device, Drug-eluting</p> <p>D Intraluminal Device</p> <p>Z No Device</p>	<p>1 Drug-Coated Balloon</p> <p>Z No Qualifier</p>
FY2025	<p>0 Abdominal Aorta</p> <p>1 Celiac Artery</p> <p>2 Gastric Artery</p> <p>3 Hepatic Artery</p> <p>4 Splenic Artery</p> <p>5 Superior Mesenteric Artery</p> <p>6 Colic Artery, Right</p> <p>7 Colic Artery, Left</p> <p>8 Colic Artery, Middle</p> <p>9 Renal Artery, Right</p> <p>A Renal Artery, Left</p> <p>B Inferior Mesenteric Artery</p> <p>C Common Iliac Artery, Right</p> <p>D Common Iliac Artery, Left</p> <p>E Internal Iliac Artery, Right</p> <p>F Internal Iliac Artery, Left</p> <p>H External Iliac Artery, Right</p> <p>J External Iliac Artery, Left</p> <p>V Foot Artery, Right</p> <p>W Foot Artery, Left</p> <p>Y Lower Artery</p>	<p>0 Open</p> <p>3 Percutaneous</p> <p>4 Percutaneous Endoscopic</p>	<p>5 Intraluminal Device, Drug-eluting, Two</p> <p>6 Intraluminal Device, Drug-eluting, Three</p> <p>7 Intraluminal Device, Drug-eluting, Four or More</p> <p>E Intraluminal Device, Two</p> <p>F Intraluminal Device, Three</p> <p>G Intraluminal Device, Four or More</p>	<p>Z No Qualifier</p>
FY2025	<p>K Femoral Artery, Right</p> <p>L Femoral Artery, Left</p> <p>M Popliteal Artery, Right</p> <p>N Popliteal Artery, Left</p> <p>P Anterior Tibial Artery, Right</p> <p>Q Anterior Tibial Artery, Left</p> <p>R Posterior Tibial Artery, Right</p> <p>S Posterior Tibial Artery, Left</p> <p>T Peroneal Artery, Right</p> <p>U Peroneal Artery, Left</p>	<p>0 Open</p> <p>4 Percutaneous Endoscopic</p>	<p>4 Intraluminal Device, Drug-eluting</p> <p>D Intraluminal Device</p> <p>Z No Device</p>	<p>1 Drug-Coated Balloon</p> <p>Z No Qualifier</p>

FY2025	K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	0 Open 4 Percutaneous Endoscopic	5 Intraluminal Device, Drug-eluting, Two 6 Intraluminal Device, Drug-eluting, Three 7 Intraluminal Device, Drug-eluting, Four or More E Intraluminal Device, Two F Intraluminal Device, Three G Intraluminal Device, Four or More	Z No Qualifier
FY2025	K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	4 Intraluminal Device, Drug-eluting	1 Drug-Coated Balloon 2 Sustained Release Z No Qualifier
FY2025	K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	5 Intraluminal Device, Drug-eluting, Two 6 Intraluminal Device, Drug-eluting, Three 7 Intraluminal Device, Drug-eluting, Four or More	2 Sustained Release Z No Qualifier
FY2025	K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	D Intraluminal Device Z No Device	1 Drug-Coated Balloon Z No Qualifier
FY2025	K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	E Intraluminal Device, Two F Intraluminal Device, Three G Intraluminal Device, Four or More	Z No Qualifier

071

FY2025	Section 0 Medical and Surgical			
FY2025	Body System 7 Lymphatic and Hemic Systems			
FY2025	Operation 1 Bypass: Altering the route of passage of the contents of a tubular body part			
Heading	Body Part	Approach	Device	Qualifier
FY2025	0 Lymphatic, Head 1 Lymphatic, Right Neck 2 Lymphatic, Left Neck 3 Lymphatic, Right Upper Extremity 4 Lymphatic, Left Upper Extremity 5 Lymphatic, Right Axillary 6 Lymphatic, Left Axillary 7 Lymphatic, Thorax 8 Lymphatic, Internal Mammary, Right 9 Lymphatic, Internal Mammary, Left B Lymphatic, Mesenteric C Lymphatic, Pelvis D Lymphatic, Aortic F Lymphatic, Right Lower Extremity G Lymphatic, Left Lower Extremity H Lymphatic, Right Inguinal J Lymphatic, Left Inguinal K Thoracic Duct L Cisterna Chyli	0 Open 4 Percutaneous Endoscopic	Z No Device	3 Peripheral Vein 4 Central Vein 7 Lymphatic K Thoracic Duct L Cisterna Chyli

OFFP

No change	Section 0 Medical and Surgical Body System F Hepatobiliary System and Pancreas Operation P Removal: Taking out or off a device from a body part			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Liver	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 2 Monitoring Device 3 Infusion Device Y Other Device	Z No Qualifier
No change	0 Liver	X External	0 Drainage Device 2 Monitoring Device 3 Infusion Device	Z No Qualifier
No change	4 Gallbladder G Pancreas	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 2 Monitoring Device 3 Infusion Device D Intraluminal Device Y Other Device	Z No Qualifier
FY2025	4 Gallbladder G Pancreas	8 Via Natural or Artificial Opening Endoscopic	0 Drainage Device	Z No Qualifier
No change	4 Gallbladder G Pancreas	X External	0 Drainage Device 2 Monitoring Device 3 Infusion Device D Intraluminal Device	Z No Qualifier
No change	B Hepatobiliary Duct D Pancreatic Duct	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Drainage Device 1 Radioactive Element 2 Monitoring Device 3 Infusion Device 7 Autologous Tissue Substitute C Extraluminal Device D Intraluminal Device J Synthetic Substitute K Nonautologous Tissue Substitute Y Other Device	Z No Qualifier
No change	B Hepatobiliary Duct D Pancreatic Duct	X External	0 Drainage Device 1 Radioactive Element 2 Monitoring Device 3 Infusion Device D Intraluminal Device	Z No Qualifier

OFW

No change	Section 0 Medical and Surgical Body System F Hepatobiliary System and Pancreas Operation W Revision: Correcting, to the extent possible, a portion of a malfunctioning device or the position of a displaced device			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Liver	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 2 Monitoring Device 3 Infusion Device Y Other Device	Z No Qualifier
No change	0 Liver	X External	0 Drainage Device 2 Monitoring Device 3 Infusion Device	Z No Qualifier
No change	4 Gallbladder G Pancreas	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 2 Monitoring Device 3 Infusion Device D Intraluminal Device Y Other Device	Z No Qualifier
FY2025	4 Gallbladder G Pancreas	8 Via Natural or Artificial Opening Endoscopic	0 Drainage Device	Z No Qualifier
No change	4 Gallbladder G Pancreas	X External	0 Drainage Device 2 Monitoring Device 3 Infusion Device D Intraluminal Device	Z No Qualifier
No change	B Hepatobiliary Duct D Pancreatic Duct	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Drainage Device 2 Monitoring Device 3 Infusion Device 7 Autologous Tissue Substitute C Extraluminal Device D Intraluminal Device J Synthetic Substitute K Nonautologous Tissue Substitute Y Other Device	Z No Qualifier
No change	B Hepatobiliary Duct D Pancreatic Duct	X External	0 Drainage Device 2 Monitoring Device 3 Infusion Device 7 Autologous Tissue Substitute C Extraluminal Device D Intraluminal Device J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier

OHR

No change	<p>Section 0 Medical and Surgical</p> <p>Body System H Skin and Breast</p> <p>Operation R Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part</p>
Heading	<p>Body Part Approach Device Qualifier</p>
No change	<p>0 Skin, Scalp 1 Skin, Face 2 Skin, Right Ear 3 Skin, Left Ear 4 Skin, Neck 5 Skin, Chest 6 Skin, Back 7 Skin, Abdomen 8 Skin, Buttock 9 Skin, Perineum A Skin, Inguinal B Skin, Right Upper Arm C Skin, Left Upper Arm D Skin, Right Lower Arm E Skin, Left Lower Arm F Skin, Right Hand G Skin, Left Hand H Skin, Right Upper Leg J Skin, Left Upper Leg K Skin, Right Lower Leg L Skin, Left Lower Leg M Skin, Right Foot N Skin, Left Foot</p> <p>X External</p> <p>7 Autologous Tissue Substitute</p> <p>2 Cell Suspension Technique 3 Full Thickness 4 Partial Thickness</p>
No change	<p>0 Skin, Scalp 1 Skin, Face 2 Skin, Right Ear 3 Skin, Left Ear 4 Skin, Neck 5 Skin, Chest 6 Skin, Back 7 Skin, Abdomen 8 Skin, Buttock 9 Skin, Perineum A Skin, Inguinal B Skin, Right Upper Arm C Skin, Left Upper Arm D Skin, Right Lower Arm E Skin, Left Lower Arm F Skin, Right Hand G Skin, Left Hand H Skin, Right Upper Leg J Skin, Left Upper Leg K Skin, Right Lower Leg L Skin, Left Lower Leg M Skin, Right Foot N Skin, Left Foot</p> <p>X External</p> <p>J Synthetic Substitute</p> <p>3 Full Thickness 4 Partial Thickness Z No Qualifier</p>

No change	0 Skin, Scalp 1 Skin, Face 2 Skin, Right Ear 3 Skin, Left Ear 4 Skin, Neck 5 Skin, Chest 6 Skin, Back 7 Skin, Abdomen 8 Skin, Buttock 9 Skin, Perineum A Skin, Inguinal B Skin, Right Upper Arm C Skin, Left Upper Arm D Skin, Right Lower Arm E Skin, Left Lower Arm F Skin, Right Hand G Skin, Left Hand H Skin, Right Upper Leg J Skin, Left Upper Leg K Skin, Right Lower Leg L Skin, Left Lower Leg M Skin, Right Foot N Skin, Left Foot	X External	K Nonautologous Tissue Substitute	3 Full Thickness 4 Partial Thickness
No change	Q Finger Nail R Toe Nail S Hair	X External	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
FY2025	T Breast, Right U Breast, Left V Breast, Bilateral	0 Open	7 Autologous Tissue Substitute	5 Latissimus Dorsi Myocutaneous Flap 6 Transverse Rectus Abdominis Myocutaneous Flap 7 Deep Inferior Epigastric Artery Perforator Flap 8 Superficial Inferior Epigastric Artery Flap 9 Gluteal Artery Perforator Flap B Lumbar Artery Perforator Flap Z No Qualifier
No change	T Breast, Right U Breast, Left V Breast, Bilateral	0 Open	J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
No change	T Breast, Right U Breast, Left V Breast, Bilateral	3 Percutaneous	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
No change	W Nipple, Right X Nipple, Left	0 Open 3 Percutaneous X External	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier

ONP

	<i>Section</i>	0 Medical and Surgical		
No change	<i>Body System</i>	N Head and Facial Bones		
	<i>Operation</i>	P Removal: Taking out or off a device from a body part		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	0 Skull	0 Open	0 Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator N Neurostimulator Generator S Hearing Device	Z No Qualifier
No change	0 Skull	3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator S Hearing Device	Z No Qualifier
No change	0 Skull	X External	0 Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device M Bone Growth Stimulator S Hearing Device	Z No Qualifier
FY2025	B Nasal Bone W Facial Bone	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator	Z No Qualifier
FY2025	B Nasal Bone W Facial Bone	X External	0 Drainage Device 4 Internal Fixation Device 5 External Fixation Device M Bone Growth Stimulator	Z No Qualifier

ONW

No change	Section 0 Medical and Surgical Body System N Head and Facial Bones Operation W Revision: Correcting, to the extent possible, a portion of a malfunctioning device or the position of a displaced device			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Skull	0 Open	0 Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator N Neurostimulator Generator S Hearing Device	Z No Qualifier
No change	0 Skull	3 Percutaneous 4 Percutaneous Endoscopic X External	0 Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator S Hearing Device	Z No Qualifier
FY2025	B Nasal Bone W Facial Bone	0 Open 3 Percutaneous 4 Percutaneous Endoscopic X External	0 Drainage Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator	Z No Qualifier

5A0

No change	<i>Section</i>	5	Extracorporeal or Systemic Assistance and Performance	
	<i>Body System</i>	A	Physiological Systems	
	<i>Operation</i>	0	Assistance: Taking over a portion of a physiological function by extracorporeal means	
Heading	<i>Body System</i>	<i>Duration</i>	<i>Function</i>	<i>Qualifier</i>
No change	2 Cardiac	1 Intermittent	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump
No change	2 Cardiac	2 Continuous	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump
No change	2 Cardiac	2 Continuous	2 Oxygenation	C Supersaturated
No change	5 Circulatory	1 Intermittent 2 Continuous	2 Oxygenation	1 Hyperbaric
FY2025	5 Circulatory	A Intraoperative	0 Filtration	L Peripheral Veno-venous
No change	9 Respiratory	2 Continuous	0 Filtration	Z No Qualifier
No change	9 Respiratory	3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	7 Continuous Positive Airway Pressure 8 Intermittent Positive Airway Pressure 9 Continuous Negative Airway Pressure A High Flow/Velocity Cannula B Intermittent Negative Airway Pressure Z No Qualifier
No change	9 Respiratory	B Less than 8 Consecutive Hours C 8-24 Consecutive Hours D Greater than 24 Consecutive Hours	5 Ventilation	K Intubated Prone Positioning

8E0

	<i>Section</i>	8	Other Procedures	
No change	<i>Body System</i>	E	Physiological Systems and Anatomical Regions	
	<i>Operation</i>	0	Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease	
Heading	<i>Body Region</i>		<i>Approach</i>	<i>Method</i>
No change	1 Nervous System		X External	Y Other Method
FY2025	2 Circulatory System		3 Percutaneous	D Near Infrared Spectroscopy F Fiber Optic 3D Guided Procedure
FY2025	2 Circulatory System		X External	D Near Infrared Spectroscopy
No change	9 Head and Neck Region		0 Open	C Robotic Assisted Procedure
No change	9 Head and Neck Region		0 Open	E Fluorescence Guided Procedure Z No Qualifier
No change	9 Head and Neck Region		3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	C Robotic Assisted Procedure E Fluorescence Guided Procedure Z No Qualifier
No change	9 Head and Neck Region		X External	B Computer Assisted Procedure F With Fluoroscopy G With Computerized Tomography H With Magnetic Resonance Imaging Z No Qualifier
No change	9 Head and Neck Region		X External	C Robotic Assisted Procedure Z No Qualifier
No change	9 Head and Neck Region		X External	Y Other Method 8 Suture Removal
No change	H Integumentary System and Breast		3 Percutaneous	0 Anesthesia Z No Qualifier
No change	H Integumentary System and Breast		X External	6 Collection 2 Breast Milk
No change	H Integumentary System and Breast		X External	Y Other Method 9 Piercing
No change	K Musculoskeletal System		X External	1 Therapeutic Massage Z No Qualifier
No change	K Musculoskeletal System		X External	Y Other Method 7 Examination
No change	U Female Reproductive System		0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	E Fluorescence Guided Procedure N Pafolacianine
No change	U Female Reproductive System		X External	Y Other Method 7 Examination
No change	V Male Reproductive System		X External	1 Therapeutic Massage C Prostate D Rectum
No change	V Male Reproductive System		X External	6 Collection 3 Sperm

No change	W Trunk Region	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	C Robotic Assisted Procedure	Z No Qualifier
No change	W Trunk Region	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	E Fluorescence Guided Procedure	N Pafolacianine Z No Qualifier
No change	W Trunk Region	X External	B Computer Assisted Procedure	F With Fluoroscopy G With Computerized Tomography H With Magnetic Resonance Imaging Z No Qualifier
No change	W Trunk Region	X External	C Robotic Assisted Procedure	Z No Qualifier
No change	W Trunk Region	X External	Y Other Method	8 Suture Removal
No change	X Upper Extremity Y Lower Extremity	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Robotic Assisted Procedure E Fluorescence Guided Procedure	Z No Qualifier
No change	X Upper Extremity Y Lower Extremity	X External	B Computer Assisted Procedure	F With Fluoroscopy G With Computerized Tomography H With Magnetic Resonance Imaging Z No Qualifier
No change	X Upper Extremity Y Lower Extremity	X External	C Robotic Assisted Procedure	Z No Qualifier
No change	X Upper Extremity Y Lower Extremity	X External	Y Other Method	8 Suture Removal
No change	Z None	X External	Y Other Method	1 In Vitro Fertilization 4 Yoga Therapy 5 Meditation 6 Isolation

X05

No change	<i>Section</i>	X	New Technology		
	<i>Body System</i>	0	Nervous System		
	<i>Operation</i>	5	Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	1 Renal Sympathetic Nerve(s)		3 Percutaneous	2 Ultrasound Ablation	9 New Technology Group 9
FY2025	1 Renal Sympathetic Nerve(s)		3 Percutaneous	3 Radiofrequency Ablation	A New Technology Group 10

X27

No change	<i>Section</i> X New Technology <i>Body System</i> 2 Cardiovascular System <i>Operation</i> 7 Dilation: Expanding an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2025	P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10

X28

FY2025	<p><i>Section</i> X New Technology</p> <p><i>Body System</i> 2 Cardiovascular System</p> <p><i>Operation</i> 8 Division: Cutting into a body part, without draining fluids and/or gases from the body part, in order to separate or transect a body part</p>				
Heading	<table border="1"> <thead> <tr> <th data-bbox="219 388 571 451"><i>Body Part</i></th> <th data-bbox="571 388 824 451"><i>Approach</i></th> <th data-bbox="824 388 1177 451"><i>Device / Substance / Technology</i></th> <th data-bbox="1177 388 1531 451"><i>Qualifier</i></th> </tr> </thead> </table>	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>		
FY2025	<table border="1"> <tbody> <tr> <td data-bbox="219 451 571 539">F Aortic Valve</td> <td data-bbox="571 451 824 539">3 Percutaneous</td> <td data-bbox="824 451 1177 539">V Intraluminal Bioprosthetic Valve Leaflet Splitting Technology in Existing Valve</td> <td data-bbox="1177 451 1531 539">A New Technology Group 10</td> </tr> </tbody> </table>	F Aortic Valve	3 Percutaneous	V Intraluminal Bioprosthetic Valve Leaflet Splitting Technology in Existing Valve	A New Technology Group 10
F Aortic Valve	3 Percutaneous	V Intraluminal Bioprosthetic Valve Leaflet Splitting Technology in Existing Valve	A New Technology Group 10		

X2R

No change	Section X New Technology Body System 2 Cardiovascular System Operation R Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2025	5 Upper Extremity Artery, Right 6 Upper Extremity Artery, Left 7 Lower Extremity Artery, Right 8 Lower Extremity Artery, Left	0 Open	W Bioengineered Human Acellular Vessel	A New Technology Group 10
FY2025	J Tricuspid Valve	3 Percutaneous	R Multi-plane Flex Technology Bioprosthetic Valve	A New Technology Group 10
No change	X Thoracic Aorta, Arch	0 Open	N Branched Synthetic Substitute with Intraluminal Device	7 New Technology Group 7

X2V

No change	<i>Section</i> X New Technology			
	<i>Body System</i> 2 Cardiovascular System			
	<i>Operation</i> V Restriction: Partially closing an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	7 Coronary Sinus	3 Percutaneous	Q Reduction Device	7 New Technology Group 7
FY2025	E Descending Thoracic Aorta and Abdominal Aorta	3 Percutaneous	S Branched Intraluminal Device, Manufactured Integrated System, Four or More Arteries	A New Technology Group 10
No change	W Thoracic Aorta, Descending	0 Open	N Branched Synthetic Substitute with Intraluminal Device	7 New Technology Group 7

XHR

No change	Section X New Technology Body System H Skin, Subcutaneous Tissue, Fascia and Breast Operation R Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
FY2025	0 Skin, Head and Neck 1 Skin, Chest 2 Skin, Abdomen 3 Skin, Back 4 Skin, Right Upper Extremity 5 Skin, Left Upper Extremity 6 Skin, Right Lower Extremity 7 Skin, Left Lower Extremity	X External	G Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy	A New Technology Group 10
No change	P Skin	X External	F Bioengineered Allogeneic Construct	7 New Technology Group 7

XRG

No change	<i>Section</i>	X New Technology		
	<i>Body System</i>	R Joints		
	<i>Operation</i>	G Fusion: Joining together portions of an articular body part rendering the articular body part immobile		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2025	A Thoracolumbar Vertebral Joint	0 Open	E Facet Joint Fusion Device, Paired Titanium Cages	A New Technology Group 10
FY2025	A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	R Interbody Fusion Device, Custom-Made Anatomically Designed	7 New Technology Group 7
FY2025	B Lumbar Vertebral Joint	0 Open	E Facet Joint Fusion Device, Paired Titanium Cages	A New Technology Group 10
FY2025	B Lumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	R Interbody Fusion Device, Custom-Made Anatomically Designed	7 New Technology Group 7
FY2025	C Lumbar Vertebral Joints, 2 or more	0 Open	E Facet Joint Fusion Device, Paired Titanium Cages	A New Technology Group 10
FY2025	C Lumbar Vertebral Joints, 2 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	R Interbody Fusion Device, Custom-Made Anatomically Designed	7 New Technology Group 7
FY2025	D Lumbosacral Joint	0 Open	E Facet Joint Fusion Device, Paired Titanium Cages	A New Technology Group 10
FY2025	D Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	R Interbody Fusion Device, Custom-Made Anatomically Designed	7 New Technology Group 7
No change	E Sacroiliac Joint, Right F Sacroiliac Joint, Left	0 Open 3 Percutaneous	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8
FY2025	J Ankle Joint, Right	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
FY2025	J Ankle Joint, Right	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
FY2025	K Ankle Joint, Left	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
FY2025	K Ankle Joint, Left	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
FY2025	L Tarsal Joint, Right	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
FY2025	L Tarsal Joint, Right	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
FY2025	M Tarsal Joint, Left	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
FY2025	M Tarsal Joint, Left	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10

XRH

No change	Section X New Technology Body System R Joints Operation H Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part																								
Heading	<table border="1"> <thead> <tr> <th><i>Body Part</i></th> <th><i>Approach</i></th> <th><i>Device / Substance / Technology</i></th> <th><i>Qualifier</i></th> </tr> </thead> <tbody> <tr> <td>FY2025 6 Thoracic Vertebral Joint 7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more A Thoracolumbar Vertebral Joint</td> <td>0 Open 3 Percutaneous 4 Percutaneous Endoscopic</td> <td>F Carbon/PEEK Spinal Stabilization Device, Pedicle Based</td> <td>A New Technology Group 10</td> </tr> <tr> <td>FY2025 B Lumbar Vertebral Joint</td> <td>0 Open</td> <td>1 Posterior Spinal Motion Preservation Device</td> <td>8 New Technology Group 8</td> </tr> <tr> <td>FY2025 B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more</td> <td>0 Open 3 Percutaneous 4 Percutaneous Endoscopic</td> <td>F Carbon/PEEK Spinal Stabilization Device, Pedicle Based</td> <td>A New Technology Group 10</td> </tr> <tr> <td>FY2025 D Lumbosacral Joint</td> <td>0 Open</td> <td>1 Posterior Spinal Motion Preservation Device</td> <td>8 New Technology Group 8</td> </tr> <tr> <td>FY2025 D Lumbosacral Joint</td> <td>0 Open 3 Percutaneous 4 Percutaneous Endoscopic</td> <td>F Carbon/PEEK Spinal Stabilization Device, Pedicle Based</td> <td>A New Technology Group 10</td> </tr> </tbody> </table>	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>	FY2025 6 Thoracic Vertebral Joint 7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10	FY2025 B Lumbar Vertebral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8	FY2025 B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10	FY2025 D Lumbosacral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8	FY2025 D Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10
<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>																						
FY2025 6 Thoracic Vertebral Joint 7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10																						
FY2025 B Lumbar Vertebral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8																						
FY2025 B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10																						
FY2025 D Lumbosacral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8																						
FY2025 D Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10																						

XW0

No change	<i>Section</i>	X	New Technology	
No change	<i>Body System</i>	W	Anatomical Regions	
No change	<i>Operation</i>	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Skin	X External	2 Anacaulase-bcdb	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	1 Daratumumab and Hyaluronidase-fihj	8 New Technology Group 8
No change	1 Subcutaneous Tissue	3 Percutaneous	2 Talquetamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	4 Teclistamab Antineoplastic	8 New Technology Group 8
FY2025	1 Subcutaneous Tissue	3 Percutaneous	6 Dasiglucagon	A New Technology Group 10
No change	1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	G REGN-COV2 Monoclonal Antibody H Other New Technology Monoclonal Antibody K Lerolimab Monoclonal Antibody	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	L Elranatamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	S COVID-19 Vaccine Dose 1	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	S Epcoritamab Monoclonal Antibody	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	1 Subcutaneous Tissue	X External	2 Anacaulase-bcdb	7 New Technology Group 7
No change	2 Muscle	0 Open	D Engineered Allogeneic Thymus Tissue	8 New Technology Group 8
No change	2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	2 Muscle	3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8

No change	3 Peripheral Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
FY2025	3 Peripheral Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	6 Afamitresgene Autoleucl Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
FY2025	3 Peripheral Vein	3 Percutaneous	8 Obecabtagene Autoleucl	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
FY2025	3 Peripheral Vein	3 Percutaneous	9 Odronektamab Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucl	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
FY2025	3 Peripheral Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
FY2025	3 Peripheral Vein	3 Percutaneous	C Zanidatamab Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5

No change	3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	L Lifleucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
FY2025	3 Peripheral Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
FY2025	4 Central Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
FY2025	4 Central Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8

No change	4 Central Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
FY2025	4 Central Vein	3 Percutaneous	8 Obecabtagene Autoleucl	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
FY2025	4 Central Vein	3 Percutaneous	9 Odronextamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucl	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
FY2025	4 Central Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
FY2025	4 Central Vein	3 Percutaneous	C Zanidatamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
FY2025	4 Central Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
FY2025	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucl Immunotherapy J Tisagenlecleucl Immunotherapy K Idecabtagene Vicleucl Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6

FY2025	4 Central Vein	3 Percutaneous	L Lifleucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
FY2025	4 Central Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	5 Peripheral Artery	3 Percutaneous	T Melphalan Hydrochloride Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
FY2025	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	J Quizartinib Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	K Sabizabulin	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	N SER-109	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	R Fostamatinib	7 New Technology Group 7
No change	G Upper GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	G Upper GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	H Lower GI	7 Via Natural or Artificial Opening	X Broad Consortium Microbiota-based Live Biotherapeutic Suspension	8 New Technology Group 8
No change	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
FY2025	J Coronary Artery, One Artery K Coronary Artery, Two Arteries L Coronary Artery, Three Arteries M Coronary Artery, Four or More Arteries	3 Percutaneous	H Paclitaxel-Coated Balloon Technology, One Balloon J Paclitaxel-Coated Balloon Technology, Two Balloons K Paclitaxel-Coated Balloon Technology, Three Balloons L Paclitaxel-Coated Balloon Technology, Four or More Balloons	A New Technology Group 10
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocogene exuparvec	6 New Technology Group 6
FY2025	U Joints	0 Open	G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System	A New Technology Group 10

No change	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7
FY2025	V Bones	3 Percutaneous	W AGN1 Bone Void Filler	A New Technology Group 10

XW1

No change	Section X New Technology Body System W Anatomical Regions Operation 1 Transfusion: Putting in blood or blood products			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	3 Peripheral Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
FY2025	3 Peripheral Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	J Exagamglogene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
FY2025	4 Central Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	J Exagamglogene Autotemcel	8 New Technology Group 8

XX2

No change	<i>Section</i>	X	New Technology		
	<i>Body System</i>	X	Physiological Systems		
	<i>Operation</i>	2	Monitoring: Determining the level of a physiological or physical function repetitively over a period of time		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Central Nervous		X External	8 Brain Electrical Activity, Computer-aided Detection and Notification	9 New Technology Group 9
FY2025	5 Circulatory		X External	0 Blood Flow, Adhesive Ultrasound Patch Technology	A New Technology Group 10
No change	F Musculoskeletal		3 Percutaneous	W Muscle Compartment Pressure, Micro-Electro-Mechanical System	9 New Technology Group 9
No change	K Subcutaneous Tissue		X External	P Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance	9 New Technology Group 9

XXA

FY2025	<i>Section</i> X New Technology			
	<i>Body System</i> X Physiological Systems			
	<i>Operation</i> A Assistance: Taking over a portion of a physiological function by extracorporeal means			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2025	5 Circulatory	3 Percutaneous	6 Filtration, Blood Pathogens	A New Technology Group 10

XXE

No change	<i>Section</i>	X New Technology		
	<i>Body System</i>	X Physiological Systems		
	<i>Operation</i>	E Measurement: Determining the level of a physiological or physical function at a point in time		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Central Nervous	X External	0 Intracranial Vascular Activity, Computer-aided Assessment	7 New Technology Group 7
FY2025	0 Central Nervous	X External	1 Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification	A New Technology Group 10
No change	0 Central Nervous	X External	4 Brain Electrical Activity, Computer-aided Semiologic Analysis	8 New Technology Group 8
No change	2 Cardiac	X External	1 Output, Computer-aided Assessment	9 New Technology Group 9
No change	3 Arterial	X External	2 Pulmonary Artery Flow, Computer-aided Triage and Notification	7 New Technology Group 7
No change	3 Arterial	X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis 6 Coronary Artery Flow, Computer-aided Valve Modeling and Notification	8 New Technology Group 8
FY2025	5 Circulatory	X External	2 Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum	A New Technology Group 10
No change	5 Circulatory	X External	3 Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	8 New Technology Group 8
FY2025	5 Circulatory	X External	4 Infection, Positive Blood Culture Small Molecule Sensor Array Technology	A New Technology Group 10
No change	5 Circulatory	X External	N Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility	6 New Technology Group 6
No change	5 Circulatory	X External	R Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure T Intracranial Arterial Flow, Whole Blood mRNA V Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection	7 New Technology Group 7
No change	5 Circulatory	X External	Y Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology	9 New Technology Group 9
No change	9 Nose	7 Via Natural or Artificial Opening	U Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction	7 New Technology Group 7

No change

B Respiratory	X External	Q Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection	6 New Technology Group 6
----------------------	-------------------	--	---------------------------------